Comparative Pharmacology
Head-to-head clinical analysis: BELSOMRA versus DAYVIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELSOMRA versus DAYVIGO.
BELSOMRA vs DAYVIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective orexin receptor antagonist that binds to OX1R and OX2R, inhibiting orexin neuropeptide signaling to promote sleep initiation and maintenance.
Orexin receptor antagonist; blocks the binding of neuropeptides orexin A and orexin B to OX1R and OX2R receptors, promoting sleep initiation and maintenance.
10 mg orally once nightly, within 30 minutes of bedtime; maximum dose 20 mg.
5 mg orally once daily immediately before bedtime; may increase to 10 mg based on efficacy and tolerability.
None Documented
None Documented
Terminal elimination half-life approximately 1 hour for suvorexant; clinical context: duration of action is longer due to high receptor binding affinity and slow dissociation.
Terminal elimination half-life is approximately 17–19 hours; supports once-daily evening dosing with sustained receptor occupancy
Primarily hepatic metabolism via CYP3A4 and CYP2C9; 83% excreted in feces (as metabolites), 6% in urine (as unchanged drug and metabolites).
Fecal (67%) as unchanged drug; renal (32%) as unchanged drug and minor metabolites
Category C
Category C
Orexin Receptor Antagonist
Orexin Receptor Antagonist